ストックスクリーナーアプリを入手
4.64
3.80%
0.17
アフターアワーズ：
4.64
前日終値:
$4.47
開ける：
$4.48
24時間の取引高:
22,447
Relative Volume:
0.06
時価総額：
$6.90M
収益：
$5.18M
当期純損益:
$-7.79M
株価収益率:
-1.9914
EPS:
-2.33
ネットキャッシュフロー:
$-4.99M
1週間 パフォーマンス:
-4.53%
1か月 パフォーマンス:
+10.21%
6か月 パフォーマンス:
-27.77%
1年 パフォーマンス:
-63.86%
1日の値動き範囲:
$4.39
$4.71
1週間の範囲:
$4.39
$4.8808
52週間の値動き範囲:
$3.54
$12.84
Evoke Pharma Inc Stock (EVOK) Company Profile
EVOK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EVOK
Evoke Pharma Inc
|
4.64 | 6.90M | 5.18M | -7.79M | -4.99M | -2.33 |
|
ZTS
Zoetis Inc
|
163.31 | 73.68B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.46 | 42.77B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.26 | 42.04B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.24 | 24.07B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.28 | 14.66B | 15.05B | -883.30M | 1.89B | -0.74 |
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-06-22 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2019-03-05 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2018-03-08 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2017-10-19 | 再開されました | FBR & Co. | Buy |
| 2017-03-16 | 繰り返されました | Rodman & Renshaw | Buy |
| 2017-01-30 | アップグレード | Laidlaw | Neutral → Buy |
| 2017-01-05 | アップグレード | Rodman & Renshaw | Neutral → Buy |
| 2016-12-23 | 繰り返されました | Rodman & Renshaw | Neutral |
| 2016-07-19 | 繰り返されました | FBR Capital | Outperform |
| 2016-07-19 | ダウングレード | Noble Financial | Buy → Hold |
| 2016-07-18 | ダウングレード | Rodman & Renshaw | Buy → Neutral |
| 2016-03-16 | 開始されました | Northland Capital | Outperform |
| 2016-03-14 | 繰り返されました | Ascendiant Capital Markets | Buy |
| 2016-02-17 | 再開されました | FBR Capital | Outperform |
| 2014-12-03 | 繰り返されました | MLV & Co | Buy |
| 2014-11-07 | 開始されました | MLV & Co | Buy |
| 2014-04-22 | 開始されました | Laidlaw | Buy |
| 2013-11-19 | 開始されました | Aegis Capital | Buy |
すべてを表示
Evoke Pharma Inc (EVOK) 最新ニュース
Head to Head Contrast: Northwest Biotherapeutics (OTCMKTS:NWBO) vs. Evoke Pharma (NASDAQ:EVOK) - Defense World
Thinking about buying stock in Agile Therapeutics, Evoke Pharma, Warner Bros Discovery, Nkarta, or Sky Harbour? - Marketscreener.com
Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com - Defense World
Financial Survey: Evoke Pharma (NASDAQ:EVOK) and Geron (NASDAQ:GERN) - Defense World
StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK) - Defense World
Siga Technologies (SIGA) Stock Surges Over 5% Amid Market Activi - GuruFocus.com
Diabetic Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma, Takeda - The Globe and Mail
Adeia Enters into Multi-Year IP License Agreement with Canon - The Manila Times
Diabetic Gastroparesis Pipeline Trends 2024: Clinical Trials, - openPR
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends - GlobeNewswire
Gastroparesis Treatment Market Generated Opportunities, - openPR
Target Corp (TGT-N) QuotePress Release - The Globe and Mail
Evoke Pharma (NASDAQ:EVOK) Now Covered by StockNews.com - Defense World
EVOK (Evoke Pharma) 5-Day RSI : 40.08 (As of Dec. 05, 2024) - GuruFocus.com
EVOK (Evoke Pharma) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com
Gray Television (GTN-N) QuotePress Release - The Globe and Mail
Mercadolibre Inc (MELI-Q) QuotePress Release - The Globe and Mail
Paramount Global Cl B (PARA-Q) QuotePress Release - The Globe and Mail
Comfort Systems USA (FIX-N) QuotePress Release - The Globe and Mail
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI® - GlobeNewswire
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
EVOK (Evoke Pharma) 5-Day RSI : 34.66 (As of Nov. 28, 2024) - GuruFocus.com
Dell Technologies Inc (DELL-N) QuotePress Release - The Globe and Mail
Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve
First Solar Inc (FSLR-Q) QuotePress Release - The Globe and Mail
Mesenchymal Stem Cells (MSC) Market Set to Surpass USD 9.72 - GlobeNewswire
Diabetic Gastroparesis Pipeline 2024: Clinical Trials - openPR
EVOK (Evoke Pharma) Total Assets : $14.15 Mil (As of Sep. 2024) - GuruFocus.com
Diabetic Gastroparesis Treatment Market: Global Size, Share, - openPR
Altium Capital Management LP Increases Stake in Evoke Pharma Inc - GuruFocus.com
Canopy Growth (CGC) Stock Dives Amid Financial Struggles and Ind - GuruFocus.com
CRON Experiences Significant Stock Dip Amid Market Volatility - GuruFocus.com
Aurora Cannabis (ACB) Shares Drop Amidst Financial Performance C - GuruFocus.com
Nasal Drug Delivery Technology Market Breakthrough in Patient Care, Projected Market Growth to USD 7.8 Billion by 2031Market Research Intellect - The Malaysian Reserve
By popular demand: SiGMA Europe launches fourth shed - GlobeNewswire Inc.
Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com - Defense World
Evoke Pharma Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Evoke Pharma earnings missed by $0.95, revenue fell short of estimates - Investing.com UK
(EVOK) Trading Advice - Stock Traders Daily
BlackLine Announces the Planned Retirement of Chief Financial Officer and Names Successor - The Manila Times
Evoke Pharma Reports Q3 2024 Financial Results - TipRanks
Canopy Growth (CGC) Stock Surges 5.2% Amid Industry Movement - GuruFocus.com
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results - The Manila Times
Nantahala Capital Management's Strategic Acquisition in Evoke Ph - GuruFocus.com
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
Ironwood Pharmaceuticals (IRWD) Sees Stock Surge Amid Positive A - GuruFocus.com
Evoke Pharma Inc (EVOK) 財務データ
収益
当期純利益
現金流量
EPS
0.58%
2.71%
大文字化:
|
ボリューム (24 時間):